

NOTICE TO THE BAR


MULTICOUNTY LITIGATION APPLICATION FOR DESIGNATION OF NEW JERSEY STATE-COURT ABILIFY CASES

The Supreme Court has received an application pursuant to Directive #08-12, "Revised Multicounty Litigation Guidelines," for Multicounty Litigation (MCL) designation of New Jersey state-court litigation against Otsuka America Pharmaceutical Inc., Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company, alleging injuries as a result of use of the drug **Abilify**.

Anyone wishing to comment on or object to this application should provide such comments or objections in writing, with relevant supporting documentation, by **January 26, 2018** to:

Hon. Glenn A. Grant
Acting Administrative Director of the Courts
Attention: MCL Comments – Abilify
Hughes Justice Complex, P.O. Box 037
Trenton, New Jersey 08625-0037

A copy of the application submitted to the Court is posted with this Notice on the Judiciary's Internet Website at (www.njcourts.gov) in the Multicounty Litigation Information Center <http://www.njcourts.gov/attorneys/mcl/index.html>.

A handwritten signature in blue ink that reads "Glenn A. Grant" followed by a stylized flourish or initials.

Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts

Dated: December 27, 2017